PIPages
Labs

Daniel Li

Stanford University, CA·Genetics·Early-career

Coronary artery disease (CAD), the narrowing of the arteries that feed the heart, is the leading cause of death worldwide. Beyond lowering cholesterol and other blood fats, there are few treatments.

Fields

Genetics

Medicine & Clinical Research

Biology

Topics

coronary artery disease

atherosclerosis

vascular smooth muscle cells

Grants
1 known grant, through Aug 2030

What they work on

  1. Determine how losing ZEB1, a transcription factor linked to coronary artery disease risk, changes gene activity, epigenetic state and plaque features in smooth muscle–derived cells, using a Zeb1 knockout mouse model of atherosclerosis.
  2. Test whether ZEB1 counterbalances its relative ZEB2 to keep smooth muscle cells in a mature state, using functional genomics and proteomics to compare the epigenetic partner proteins each factor recruits.
  3. Define how ZEB factors interact with other coronary artery disease–associated genes, using single-cell genomics in animal and human models to connect genetic risk to smooth muscle cell transitions.

More about the research

A key reason is that scientists cannot yet connect inherited risk genes to the processes that actually cause disease. Smooth muscle cells (SMCs), the cells that form the muscular wall of blood vessels, are central here. During atherosclerosis, the build-up of fatty plaques in artery walls, SMCs lose their mature identity and migrate out of the vessel wall to help form a fibrous cap over the plaque. SMCs are also the main cell type carrying genetic susceptibility to CAD.

Why it matters

Most coronary artery disease treatments target cholesterol, leaving a gap in options. By showing how the CAD risk genes ZEB1 and ZEB2 control smooth muscle cell behavior in artery walls, this work could support better tools for predicting a person's risk and point to precision therapies. Such advances may help prevent heart attacks.

Known grants

From NIH and NSF research grants. Labs often have other funding we can't see.

ZEB1 Mediated Coronary Artery Disease Risk in Vascular Smooth Muscle

NIH · Sep 2025 – Aug 2030

Closest labs

Robert Wirka

University of North Carolina at Chapel Hill, NC·Genetics

Track individual smooth muscle cells as they multiply and choose fates during atherosclerosis, using a barcoding mouse model compatible with single-cell RNA sequencing, with and without Twist1 knockout.

Joseph Miano

Augusta University, GA·Physiology

Define the coronary artery disease that develops in mice lacking Lmod1 only in vascular smooth muscle cells, using mouse genetics, spatial gene-activity profiling and immuno-electron microscopy of artery tissue.

Clint Miller

University of Virginia, VA·Genetics

Determine how FHL5, a helper protein that tunes gene activity, causes vascular dysfunction through the actin cytoskeleton, the extracellular matrix and vessel constriction. The work will use human vascular cells and arteries studied ex vivo.

The school

Stanford University: 87 labs on PI Pages, $1.6B a year on research, 739 research doctorates a year.

More about Stanford University

Reach out

A start for your email. Fill in the brackets.